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Introduction: Children with congenital hemiplegia often present with limitations in using their impaired upper limb
which impacts on independence in activities of daily living, societal participation and quality of life. Traditional therapy
has adopted a bimanual training approach (BIM) and more recently, modified constraint induced movement therapy
(mCIMT) has emerged as a promising unimanual approach. Evidence of enhanced neuroplasticity following mCIMT
suggests that the sequential application of mCIMT followed by bimanual training may optimise outcomes (Hybrid
CIMT). It remains unclear whether more intensely delivered group based interventions (hCIMT) are superior to
distributed models of individualised therapy. This study aims to determine the optimal density of upper limb training
for children with congenital hemiplegia.
Methods and analyses: A total of 50 children (25 in each group) with congenital hemiplegia will be recruited to
participate in this randomized comparison trial. Children will be matched in pairs at baseline and randomly allocated to
receive an intensive block group hybrid model of combined mCIMT followed by intensive bimanual training delivered
in a day camp model (COMBiT; total dose 45 hours direct, 10 hours of indirect therapy), or a distributed model of
standard occupational therapy and physiotherapy care (SC) over 12 weeks (total 45 hours direct and indirect therapy).
Outcomes will be assessed at 13 weeks after commencement, and retention of effects tested at 26 weeks. The primary
outcomes will be bimanual coordination and unimanual upper-limb capacity. Secondary outcomes will be
participation and quality of life. Advanced brain imaging will assess neurovascular changes in response to treatment.
Analysis will follow standard principles for RCTs, using two-group comparisons on all participants on an intention-
to-treat basis. Comparisons will be between treatment groups using generalized linear models.
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Congenital hemiplegia occurs in over one million chil-
dren under 21 years of age in the industrialised world
and is the most common type of cerebral palsy (CP), ac-
counting for 36% diagnosed with this lifelong condition
[1,2]. These children have limitations in their capacity to
use their impaired upper limb and bimanual coordin-
ation deficits which impacts upon daily activities and
participation in home, school and community life [3].
There are currently two diverse intensive therapy ap-
proaches aimed at improving upper limb performance.
Traditional therapy has adopted a bimanual training ap-
proach (BIM) and more recently, constraint induced
movement therapy (CIMT) has emerged as a promising
unimanual approach.
Our 2009 published meta-analysis evaluating the effi-
cacy of all non-surgical approaches to upper limb re-
habilitation highlighted the absence of strong evidence
for any particular model of therapy for improving upper
limb outcomes in congenital hemiplegia [4]. There was
consistent evidence for a small supplementary benefit
for use of intramuscular Botulinum Toxin A (BoNT-A)
injections combined with various models of upper limb
training. No particular model of training, whether it was
Neurodevelopmental Therapy (NDT), CIMT or Inten-
sive Hand Arm Bimanual Training (HABIT) demon-
strated a superior effect on activity limitations [4]. In
the last three years, a significant number of additional
randomised controlled trials, particularly of CIMT have
been published [Sakzewski L, Ziviani J, Boyd RN: Effi-
cacy of upper limb interventions for children with
unilateral cerebral palsy: systematic review and meta-
analysis update, submitted].
Classic CIMT involves application of a full arm cast to
the unimpaired upper limb which is worn for 21 con-
secutive days and accompanied by six hours daily of
upper limb training (total dose 126 hours) [5]. This
model of therapy, initially used with adults post stroke,
demonstrated significant improvements in upper limb
function that were retained at 12 months post interven-
tion [6]. The classic CIMT model has been used in a
small number of studies for children with congenital
hemiplegia demonstrating improved quality and amount
of use of the impaired upper limb and acquisition of
new upper limb motor skills [5,7]. A subsequent studycompared the full classic CIMT protocol to half dose
(60 hours) and demonstrated that for three to six year
old children with congenital hemiplegia, 63 hours of
training was sufficient to drive changes in upper limb
function [5,8].
Classic CIMT has been criticised for not being child
friendly or clinically feasible to implement. A significant
number of modified CIMT (mCIMT) models have been
developed. These have varied from intensive group based
interventions [9-12], intensive individual therapy [13,14],
distributed group or individual intervention [16-21] deliv-
ered either in the clinic [9,10], community [11], or in the
home [14,15,17,20,21]. Despite the different modes of
delivery and environmental context, findings consist-
ently demonstrate mCIMT is superior to standard or
usual care of a lesser dosage to improve quality and
amount of use of the impaired upper limb [17,21], bi-
manual and unimanual efficiency of movement [17,21]
and bimanual performance [16].
In contrast, when mCIMT has been compared to an
equivalent dose of intensive bimanual training or goal
directed occupational therapy, minimal differences have
been found on most clinical measures, as both interven-
tions yield similar improvements [10,11,13]. This high-
lights that the dose of therapy may be the critical
ingredient rather than the type of therapy (e.g. unimanual
versus bimanual).
Constraint induced movement therapy and modified
protocols have a significant limitation, that is, they do
not allow practice of bimanual tasks. Goals identified by
children and their caregivers tend to be bimanual in na-
ture [11,19]. This has led to the development of hybrid
models of therapy that combine mCIMT and bimanual
training. Two studies have investigated differing hybrid
models of mCIMT followed by bimanual training. A
long duration, distributed model of therapy performed
over an eight week period (six weeks mCIMT 54 hours;
two weeks bimanual 18 hrs) found significant gains in
unimanual, bimanual and individualised outcomes com-
pared to standard care for 2.5 to eight year old children
with congenital hemiplegia [22]. A short duration model
delivered over a three week period (two weeks mCIMT
30 hrs, one week bimanual 2.25 hrs), however was not
superior to usual care to improve movement efficiency
but did yield significant changes in self-care [23].
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dosage, the choice of outcome measures, and intensity
or density of training. Recent classic CIMT studies have
also acknowledged the need for bimanual training to fol-
low CIMT and have developed a “transfer package” to
address this requirement [7,24]. Further support for the
idea of sequential application of interventions was
obtained from examination of neuroplasticity findings
with Transcranial Magnetic Stimulation (TMS). Chil-
dren receiving mCIMT had greater and earlier use-
dependent neuroplasticity than those receiving BIM (in
a masked comparison) immediately post intervention
which was sustained at six months [25]. This has im-
portant implications for the timing of interventions and
the potential for optimizing the strengths of both by se-
quential application.
There is currently little evidence to support traditional
standard care block models of upper limb therapy (e.g.
six to eight weekly one hour sessions), as these alone are
unlikely to provide an adequate dose to drive changes in
upper limb function. Occupational therapy home pro-
grams have been shown to be effective in a high quality
randomised controlled trial [26] and could allow an ad-
equate dose of therapy to be achieved if accompanied
with a distributed block model of intervention. As little
as 15 minutes of home program practice four times per
week over an eight week block of therapy was shown to
be effective in improving functional goals and quality of
upper limb skills (Quality of Upper Extremity Skills
Test) [26]. It remains unclear whether a more intensive
model of upper limb training is superior to a distributed
standard care model augmented by a functionally fo-
cused home program to achieve a similar dosage of ther-
apy to improve upper limb unimanual, bimanual and
individualized outcomes.
This current study proposes a hybrid model which will
sequentially combine modified constraint induced move-
ment therapy (mCIMT) followed by intensive bimanual
training (called COMBiT) and compare this to a stand-
ard upper limb training model in a randomised trial. We
propose to compare the intensive group based COMBIT
model (one week of 30 hours of mCIMT followed by
one week of 30 hours of bimanual training of which 45
hours was direct and 10 hours of indirect upper limb
training) to standard care delivered in an individualised
and distributed model (standard occupational therapy
(OT); total dose 45 hours direct and indirect over 12
weeks) for improving outcomes as they pertain to activ-
ity and participation for children with congenital hemi-
plegia. Standard care for children with congenital
hemiplegia will be six weekly sessions of 1.5 hours of
OT provided in an individualised format (9 hours direct)
in combination with an individually designed home pro-
gram delivered over a 12 week period (36 hours indirecttraining). Each approach, COMBiT or standard care may
follow intramuscular BoNT-A injections to the forearm
provided as part of standard clinical practice that is de-
livered to reduce forearm spasticity prior to upper limb
training.
We intend to determine if COMBiT is effective in pro-
viding a superior and lasting benefit, compared to stand-
ard therapy. As therapy programs are resource intensive
and time consuming it is important to determine if an
intensive program such as COMBiT is superior to stand-
ard distributed models of conventional therapy for im-
proved and sustained outcomes. If the effects of COMBiT
are sustained and superior over a six month period this
could offer a cost effective, timely model of care. This
study has been funded by the National Health and Med-
ical Research Council (NHMRC) of Australia (Project
Grant 1003887).
Methods and analyses
A matched pairs randomised comparison trial will be
conducted to evaluate whether a novel rehabilitation
model (COMBiT) will be more effective than conven-
tional standard care (OT) for improving upper limb
function in children with congenital hemiplegia.
The primary hypothesis to be tested is:
H1 COMBiT will reduce activity limitations (improve
unimanual capacity and bimanual performance) to a
greater extent than standard care.
The secondary hypotheses are:
H2 Use dependent neuroplasticity and neurovascular
changes (fMRI) will be more extensive and retained for
a longer duration in children undertaking COMBiT
than those engaged in standard care.
H3 COMBiT will be more effective compared with
standard care to increase participation and enhance
quality of life.
Two broad aims will be addressed:
The primary aim of our study is to determine which
model of upper limb training leads to greater changes
in upper limb activity performance and whether
changes are maintained to six months post
intervention.
A secondary aim is to further our understanding of the
central neurovascular mechanisms underlying changes
in upper limb function according to the type of training
applied. Improving our understanding of the
mechanisms underpinning treatment efficacy is an
essential next step towards providing effective
treatment and sustained outcomes. In addition,
Boyd et al. BMC Neurology 2013, 13:68 Page 4 of 17
http://www.biomedcentral.com/1471-2377/13/68understanding the nature and timing of the brain lesion
and relationship to treatment response may assist with
effective allocation of resources.
Ethical considerations
Full ethical approval has been obtained by the Medical
Ethics Committee of The University of Queensland
(2011000553), The Royal Children’s Hospital Brisbane
(HREC/11/QRCH/37) and The Cerebral Palsy League
Ethics Committee (CPL-2012-004). Trial registration has
been obtained with the Australian and New Zealand
Clinical Trials Registry: (ACTRN12613000181707). In-
formed, written consent will be obtained from all parents
or guardians and assent from participants (if 12 years of
age or older) before entering the trial.
Study sample and recruitment
Fifty children and youth with spastic hemiplegia aged 5–
16 years will be recruited across Queensland, Australia.
Potential study participants will be identified through a
population-based research database, which currently
comprises of over 1300 children with CP at the Queens-
land Cerebral Palsy and Rehabilitation Research Centre
(QCPRRC), the Queensland Cerebral Palsy Register
(QCPR), Queensland CP Health Service, Queensland
Cerebral Palsy League and advertising to Occupational
Therapists, Physiotherapists and Paediatricians at the
Royal Children’s Hospital, Brisbane and in the commu-
nity. The recruitment process will target both publicly
funded services and private practitioners with the ex-
pectation that the sample will be representative of chil-
dren with congenital hemiplegia.
Inclusion criteria
The study will include school aged children and youth:
(1) With a confirmed diagnosis of congenital
hemiplegia.
(2) Aged five to 16 years.
(3) Who have reduced upper limb function due to
predominant spasticity rather than dystonia.
(4) Who can provide sufficient co-operation and
cognitive understanding to participate in the
therapy activities.For a subset of children performing the Advanced
Brain Imaging studies further inclusion criteria are:i Sufficient co-operation to perform Advanced Brain
Imaging studies for 45 minutes.
ii No exclusions for 3 Tesla Magnetic Resonance
Imaging (3T MRI) including no metal implants, noshunts, no uncontrolled epilepsy as the later would
be a confound.
Exclusion criteria
Participants will be excluded if they have:
(1) Fixed contracture or severe muscle spasticity in the
designated muscle groups.
(2) Previously undergone surgery in the upper limb
(UL).
(3) Received BoNT-A injections within six weeks prior
to baseline assessments.
Sample size
The primary basis for sample size calculation for this
study is adequate power for the primary hypothesis: H1
comparison between the functional effects of COMBiT
compared to standard care at 26 weeks. Based on data
from the previous study [25] a mean difference of 7
units (10% of the control group mean at baseline on the
Melbourne Assessment of Unilateral Upper Limb Func-
tion (MUUL) is proposed as the minimum difference
likely to have clinical implications [27,28]. We assume a
standard deviation of 9 units. Based on a comparison
with alpha = 0.05 and 80% power, 25 subjects in each
group (n=50) are required.
For H2, our previous upper limb has shown 90% suc-
cess on 3 repeated fMRI scans [25]. Using 3T fMRI we
can see activation in the representative cortex for motor
studies with good signal to noise ratio. We allow for some
loss of information due to subject refusal (10%) and scans
where motion is a confounder (10%). With 40 participants
in an analysis of baseline to week 13 changes on fMRI, this
study will have 80% power to detect a difference between
groups of 0.9 SDs. If we consider the supplementary
motor area (SMA) given coefficients of variation (COV)
for control subjects performing motor tasks (COV of 11%
in PM1 and 35% in SMA) [29] and activation signal of
1.5%, we are able to detect differences in percentage acti-
vation levels over time as small as 0.47.
Randomisation
Following baseline assessments, children will be ran-
domised within matched pairs to receive either COMBiT
or standard care. To maximise homogeneity of the sam-
ple and minimise group differences at baseline, matching
in pairs will be completed according to age (12 month
bands), gender, and Manual Ability Classification Sys-
tem (MACS) level [30]. Treatment allocation will be
recorded on a piece of folded paper inside a concealed
opaque envelope. Using a sequence of computer-
generated random numbers the number “1” or “2” will
be allocated to each member of the pair. As each pair is
randomised, they will be allocated the next consecutive
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who will read and record the treatment allocation. Study
personnel will be informed of group allocation.Study procedure
Children will attend either the Royal Children’s Hospital
or The University of Queensland in Brisbane for base-
line and follow up assessments. Children randomised to
COMBiT will participate in a two week day camp dur-
ing school holidays commencing within one month of
baseline assessments. Participants randomised to stand-
ard care will be allocated a local therapist and individual
therapy sessions will commence within one month of
baseline assessments. The experimental design and out-
come measures are depicted in Figure 1.Key:-
AHA- Assisting Hand Assessment. BBT- Box and 
Experience Questionnaire. CPQoL- Adult, Cerebra
Cerebral Palsy Quality of Life – Child. COPM- Can
Child/Teen, Dimensions of Mastery Questionnaire 
Mastery Questionnaire – Parent. GMFCS – Gross M
Jebsen Taylor Test of Hand Function. LIFE-H- Ass
Classification System. MUUL- Melbourne Assessm
Physical Upper Limb Assessment. SQ- Study Ques
Parenting Scale Questionnaire. PVQ- Pediatric Vol
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Figure 1 CONSORT flow chart for COMBiT trial.Study interventions
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ect UL therapy). The COMBiT and the standard care pro-
grams will have the same dosages of upper limb therapy
(COMBIT: 45 hours direct UL training; Standard care
(SC): nine hours direct UL training and 36 hours indirect
UL therapy). They will differ by (i) delivery method (block,
group model versus distributed individualised model) (ii)
varied construct (mCIMT versus goal directed training)
and (iii) different environment.
(i) COMBIT: combined modified Constraint Induced
Movement Therapy & Bimanual training
In mCIMT, the unimpaired arm is constrained in an in-
dividually made glove and combined with intense prac-
tice of tasks to promote use of the impaired arm. In
BIM, equal use of both hands is trained by engaging in
bimanual tasks. During the mCIMT program, all thera-
peutic activities, circus activities, occupational tasks such
as preparation and cleaning up of activities and all meal-
times will be performed predominantly with the impaired
hand and the unimpaired hand will be constrained in a
glove. In situations where the task demands use of two
grasping hands, the participants will be required to co-
operate with each other (in pairs) to complete the task
with their impaired hands. This will be followed in the
second week by an equal dose of BIM where bimanual use
of both hands during all therapeutic activities, circus activ-
ities and occupational tasks will be required.
COMBiT will be conducted over two weeks of the
school holidays in a “day camp model”. Participants will
attend a community facility “Flipside Circus” for six hours
a day, five days a week from 9am to 3pm. In total, 45
hours of the day camp program will directly target upper
limb training, and 10 hours will provide indirect use of the
UL in more general gross motor upper limb activities. For
both mCIMT and BIM training, the content will include
intensive activity based practice, circus activities as well as
self-care and recreational activities. The group will be led
and supervised closely by five to seven therapy staff to
achieve a ratio of one trainer to two children. Five core oc-
cupational therapists and one physiotherapist will plan
and lead all intervention groups. Daily grading of activities
and modification of tasks for the participants in each
group will be performed by the core therapists. Tasks and
activities will focus on reducing upper limb activity limita-
tions identified at baseline assessment and target three oc-
cupational performance goals identified by the parents
and/or child. Planning activities for each group will re-
quire task analysis, and develop guidelines for grading to
challenge children with varying capabilities. Specific de-
tails of the content of the COMBiT weekly program con-
tents are presented in Additional file 1: Table S1. Prior to
commencement of the daily program, staff will be briefed
and given specific tasks with written instructions outlininghow each activity will be performed for the specific chil-
dren they are supervising. Professional circus trainers will
lead the two hour circus workshops. The core therapy
team will meet with the circus trainers to design these
programs and at the end of each session to discuss and
modify the program as required and provide guidance to
grading of tasks for participants. A debriefing session for
the entire COMBiT group with staff members and separ-
ately for the staff and volunteers will be conducted at the
conclusion of each day. The core therapy team will also
meet daily to review individual participants’ goals and con-
tinually grade their program. A daily record of attendance
will be kept and anecdotal information from the day will
also be recorded.
(ii) Standard care upper limb rehabilitation
Standard care comprises an individualised and distrib-
uted model of occupational therapy upper limb training
which consists of six sessions of 1.5 hours of individual
direct therapy provided in a hospital or community set-
ting over six weeks in combination with a 12 week home
program. The weekly 1.5 hour sessions comprise one hour
of direct therapy, and half an hour for home program de-
velopment, demonstration and training with a total dose
of nine hours of direct therapy. Families will be provided
with a home program to practice goal areas for 12 weeks
from the commencement of individual therapy sessions
(30 minutes daily practice for six days/week for 12 weeks)
for a total dose 36 hours of indirect UL therapy for the
standard care group. The total anticipated therapy dose
for standard care including direct therapy and home pro-
gram practice is 45 hours of training.
Concurrent therapies
During the study children will not be provided with any
additional concomitant upper limb treatments, such as
arm splinting, casting or additional upper limb training.
Children will return to their regular therapy programs at
the completion of the 13 week follow up assessments.
Documentation of concurrent therapy programs (ongoing,
additional therapy or interventions, change in spasticity
medications or lower limb interventions) will be recorded
at each follow up assessment as these would not be able
to be controlled over a six month period.
Study duration
Children will be recruited in blocks of 24 to 26 children
at six monthly intervals to enable sessional testing of fMRI
and training. The children will attend day camps during a
holiday period. Recruitment will take 12 months, as suit-
able candidates could be drawn from our QCPRRC regis-
ter (n=180 potential children). Potential participants can
receive upper limb intramuscular BoNT-A injections prior
to study entry as part of clinical practice. Entry into the
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whom have received intramuscular BoNT-A injections in
the forearm to reduce spasticity.
Measures
Classification measures
a) Manual Ability Classification system (MACs) The
MACS classifies the child’s ability to handle objects in
daily activities on one of five levels [30]. The MACs has
reported construct validity, and excellent inter-rater reli-
ability (ICC=0.97 between therapists and 0.96 between
therapists and parents) [30]. Children in the study will
be MACS level I – III.
b) Gross Motor Function Classification System
(GMFCS) The GMFCS classifies the child’s ability to
carry out self-initiated movements related to sitting and
walking across five levels [31]. The GMFCS has strong
construct validity with the Gross Motor Function Meas-
ure (r=0.91) [32] and good inter observer reliability
between professionals and between professionals and
parents [33,34]. In this study sample of children with
hemiplegia, it is expected that all children in the sample
will be GMFCS level I or II.
c) Zancolli scale The Zancolli Scale [35] classifies sever-
ity of forearm alignment by measuring the contribution
of spasticity and muscle length in the wrist and finger
flexors in active wrist and finger extension. Three levels
range from I (minimal flexion spasticity, complete exten-
sion of fingers with wrist in neutral position or less than
twenty degrees of flexion) to III (severe flexion spasticity,
no extension of fingers even with maximal wrist flexion).
It is expected that participants will have either a Zancolli
score level I or II.
d) House functional classification scale The House
Functional Classification Scale [36] consists of nine
grades ranging from 0 (does not use) to 8 (full spontan-
eous use) to rate functional use of the impaired upper
limb.
e) Classification of the brain lesion The nature of the
brain lesion will be classified using Magnetic Resonance
Imaging (MRI) by a Child Neurologist. The classification
system to be used is based on the presumed timing and
nature of the insult that resulted in CP including both
genetic and non-genetic aetiologies such as cortical
malformations & hypoxic ischaemic injury [37,38]. Brain
lesion severity will be assessed using a structured scoring
proforma [39] based on the CH2 template [40], a highly
detailed single-subject T1 template in MNI space, which is
the international standard for brain mapping (International
Consortium of Brain Mapping - ICBM). Lesions will betranscribed onto the proforma and the following measures
obtained: number of (i) anatomical lobes involved, (ii)
number of slices on the template that were impaired and
(iii) size and distribution of the lesion measured by a total
lesion score.
Neurovascular measures
a) Whole-brain functional MRI studies We have pre-
viously used functional Magnetic Resonance Imaging
(fMRI) to examine functional reorganisation [41,42] and
have combined this with TMS to localise the (re)organisa-
tion of the motor cortex in children with CP [25]. Func-
tional MRI or blood oxygen level dependent (BOLD)
contrast is a robust and non-invasive method of detection
of regional tissue changes in venous oxygenation in re-
sponse to task related activation [43].
Functional imaging will be performed at 3 Tesla on a
Siemens MAGNETOM Trio MR scanner at the Centre
for Advanced Imaging (CAI), at the University of
Queensland. Use of 3T will reduce the time in the scan-
ner for children and improve the resolution of data col-
lected compared to 1.5T. To prepare for the real fMRI
scan all children will practice in a mock MRI scanner
using techniques that have achieved 90% compliance in
our earlier studies [25]. During scanning of their ana-
tomical images, the children will be able to watch a
favourite video. Children will lie supine, with their head
immobilised with an immobilisation pad to minimise
head movement. In the scanner, children will perform
two motor tasks, simple active wrist extension at 2 Hz
and a complex motor task. These tasks are frequently
impaired in children with hemiplegia and most likely to
show a response to training. The motor paradigm will
consist of a 2-condition block design, visually cued via in-
structions projected on a screen. The baseline condition is
no movement. A recording of a metronome at 2 Hz will
provide an auditory cue for the rate of movement. Verbal
cues to commence and end the task will be given. The
task and rest periods are 30 seconds with the activation
cycle repeated four times.
Children with sufficient comprehension will also
complete an additional complex motor task in the scan-
ner. This is a timing versus sequencing task performed
in a block design (two runs of six minutes each), where
the subject alternates between a block of single index
finger button pressing with a block of random sequences
of 3-finger button presses. For the sequence task, visual
cues of “123, 321, 213” numbers to denote a random se-
quence of pushing three buttons with their index, third
and fourth fingers with their dominant hand. This com-
plex task is designed to differentiate activation in the
primary motor cortex and different aspects of the basal
ganglia circuit. The rationale behind the simple and
complex movement is based on previous studies that
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of the motor cortex and basal ganglia circuits [44]. Not-
ably increased complexity of finger movements in-
creases activation of the basal ganglia circuit, and thus
provides an ideal model to utilise fMRI to locate func-
tion specific regions of the cortex associated with finger
movements.
An additional five minutes of resting-state fMRI will
also be collected for analysis of functional connectivity
immediately after the motor tasks. Tasks performed prior
to resting-state fMRI can influence functional connectivity
[45], so the resting-state data will be collected after the
motor paradigms have been completed to provide
consistency. The whole assessment will take no longer
than 50 minutes in the scanner. The actual movements
performed in the scanner will be rated for speed, the range
of motion actually performed, ability to isolate the move-
ment and presence of mirror movements in the contralat-
eral hand or general body movements for the active motor
task and the number and timing on correct button se-
quences in the complex motor task.
Functional MRI will be acquired using a BOLD acquisi-
tion sequence (Gradient-recalled-echo (GRE) echo-planar
imaging (EPI), Repetition Time (TR)=3.0s, Echo Time
(TE)=30 ms, Flip angle = 85°, Slice thickness=3 mm,
FOV=216 mm, 44 slices, 72 × 72 matrix yielding an in-
plane resolution of 3.0 mm × 3.0 mm). A single set of T2-
weighted anatomical, FLAIR and 3D T1 volumes will also
be collected. Functional MRI image processing, analysis
and visualisation will be performed using iBrain™ software
[41], SPM8 analysis software (Wellcome Department of
Imaging Neuroscience, London, UK) and the iBrain™ Ana-
lysis Toolbox for SPM [46].
Pre-processing of the fMRI images will include slice-
timing correction using a temporal interpolation scheme
to estimate the response at the time of commencement
of each acquisition volume, motion correction (realign-
ment) within session and nonlinear registration across
sessions for each participant, and spatial normalisation
to the standard Montreal Neurological Institute (MNI)
template supplied with SPM. In the realignment step,
images within a session will be aligned to a single target
image within that time series to minimise the effects of
participant motion between scans. The target selected by
iBrain™ is the image whose within-brain centre-of-mass
is located closest to the median of all images in that time
series. Target images from each session of a subject will
then be non-linearly spatially normalised to a subject-
specific space in an iterative fashion in a manner similar
to that described in Wilson & Abbott et al. [47] to en-
sure unbiased registration of images across sessions; this
step is designed to correct, as far as practicable, non-
linear image distortions that may differ from session to
session. The step will be undertaken within subjectrather than directly to the standard template to maxi-
mise the fidelity of within-subject registration. The mean
of the within subject registered images will then be
spatially normalised to the standard MNI template. Be-
cause many participants have large lesions, spatial nor-
malisation to the MNI template will be undertaken
using only an affine transform. In practice, the image
transformations derived in each step described above
will first be combined and then applied in one step to
minimise resampling artefact when writing the final im-
ages. The spatially normalised image data will be
smoothed with an isotropic Gaussian kernel at least
twice the voxel size to fulfill the assumptions of Gauss-
ian random field theory (RFT). Using generalized linear
models (GLMs), statistical parametric maps will be
computed for each session of each subject. Temporal
autocorrelation will be modeled using a white noise
and autoregressive AR(1) model within SPM. Motion
correction parameters will be included as covariates of
no interest. Details regarding the specific implementa-
tion of the GLM and RFT by SPM are available else-
where [48]. Gross motion will be removed using scan-
nulling regressors that account for all the variance in
the motion-affected scan and the following three scans
(to avoid possible T1 effects) [49]. Gross motion will be
defined as motion exceeding 0.5 mm from one scan to
the next, as heuristically this appears to sufficiently
mitigate the confound in functional connectivity stud-
ies where the effect can be the most confounding [50].
Due to the heterogeneity in lesion location and size
across participants, group analysis of intra-participant
change in activation will be undertaken using a region
of interest approach with the assistance of iBrain™
software. Laterality of regions will be quantitatively
assessed using a method adapted from [51].
b) Diffusion imaging acquisition and white matter
fibre tracking In addition to a number of standard
radiological scans (T1, T2, FLAIR and 1 mm isotropic
MPRAGE structural scan), diffusion-weighted images suit-
able for tractography studies will be acquired using a fully
optimised single-shot, spin-echo echo-planar diffusion se-
quence. Diffusion weighted MRI data will be acquired to
probe microstructural changes in white matter tracts de-
lineated using tractography. The diffusion weighted data
will be acquired using a 64-directional single-shot spin-
echo echo-planar imaging sequence with the following
imaging parameters: TR/TE 9500/116 ms; acquisition
matrix 128 × 128 with field of view 30 × 30 cm (resulting
in an in-plane resolution of 2.35 × 2.35 mm); 60 axial
slices of thickness 2.5 mm; 64 non-collinear diffusion en-
coding directions; b-value 3000 s/mm2. The total imaging
time for this sequence is 10 minutes. To reduce image dis-
tortions, an acceleration factor of 2 will be used, and a
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residual distortions.
White matter fibre orientation distributions will be es-
timated using constrained spherical deconvolution [52]
using MRtrix software [53], which allows the resolution
of crossing fibres which is critically important for fibre-
tracking [54]. Whole brain probabilistic tractography will
be carried out using MRtrix. White matter pathways will
be extracted using cortical and subcortical target regions
identified in an automated fashion from high-resolution
structural images using freesurfer (http://surfer.nmr.mgh.
harvard.edu/). Alterations in white matter microstructure
within these pathways will be assessed using traditional
diffusion tensor imaging (DTI) metrics - including frac-
tional anisotropy (FA) and mean diffusivity (MD) - as well
as the novel apparent fibre density (AFD) measure [55]
which takes into account the presence of crossing fibres.
Tractography will be used to delineate individual pathways
as described previously [56-58], and for connectivity-
based parcellation [59,60]. Changes in white matter micro-
structure within delineated pathways following therapy
will be assessed.
Body functions and structures
The positive features of the upper motor neurone (UMN)
syndrome will be measured at baseline to grade the sever-
ity of impairment in each group and to compare severity
between the groups. Passive range of motion will be
assessed primarily for the impaired shoulder, elbow, fore-
arm, wrist flexors, fingers and thumb adductors using
goniometry [61]. Spasticity will be measured using the
Modified Tardieu Scale [62] at fast velocity in the forearm
agonists and the Modified Ashworth Scale [63,64] in the
same muscle groups.
The negative features of the UMN syndrome will be
measured to describe the sample and to analyse their
impact on outcome as a co-variate. Each test will be
performed in both the impaired (hemiplegic limb) and un-
impaired (hand writing limb) to compare sensory function
between limbs. The following aspects of sensory impair-
ment will be measured:
(i.) Stereognosis. will be assessed on the impaired
and unimpaired limbs using the approach
originally described by Feys [65]. Stereognosis
was assessed according to a protocol using two
sets of nine common objects, three familiar
objects (key, spoon and peg) and six similar
paired objects (button/coin, paperclip/safety pin
and pen/pencil) [66]. With vision occluded,
children will be presented with each item. A
corresponding set of items will be used to allow
children to identify the object in order to
minimise any errors due to correct naming of theobject. Scores ranged on a scale between 0–9,
where participants scoring below 9/9 were
considered to have impaired stereognosis [67].
(ii.) Moving two point discrimination (M2PD) will be
measured using the Disk-criminator® (Baltimore,
Maryland) on both the impaired and unimpaired
limbs. Either one or two points will be randomly
applied in continuous moving firm contact
longitudinally to the pulp of the index finger with
vision occluded [68]. The minimum distance
participants can usually distinguish between two
discrete points ranges from 2mm (normal) to 15
mm (poor) [66,69].
(iii.)Texture Tactile Perception will be tested using the
AsTex perspex board that displays tactile gratings
of reducing tactile discrimination index [70].
Starting at the “rough” end of the board,
movement of the child’s index finger, then thumb,
then fifth finger will be guided by the examiner
along the board at a constant speed in a
standardized manner. Children will be instructed
to stop immediately when the board feels smooth
(gratings became too close together to determine
their separation). Each point will be recorded, with
the final outcome the average of three trials for
each digit. The averaged scores will be converted
to the tactile discrimination index for each finger
using the chart available with the test kit.
(iv.) Grip strength will be measured using a hand held
dynamometer (Smedley, Takei Scientific
Instruments Co Ltd). Grip strength will be
measured for the average of three attempts on the
impaired and unimpaired limbs (kilograms force,
Kgf) [71].
(v.) Mirror movements will be assessed and scored in
each hand on the side of the body unintentionally
performing the movement during three unimanual
UL tasks: (i) rapid tapping of the index finger on
the distal thumb, (ii) alternating supination and
pronation of the forearm and (iii) repetitive
alternate touching of each fingertip to the tip of
the thumb of the same hand, in order.
Participants will be videotaped and scored on a
four point scale ranging from no clearly
imitative movements to movement equal to that
of the intended hand with a possible total score
ranging from 0-12 [72].Primary outcomes
There will be a primary outcome measure for upper limb
bimanual co-ordination (the Assisting Hand Assessment)
and unimanual capacity (The Melbourne Assessment of
Unilateral Upper limb Function).
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(i) Assisting Hand Assessment (AHA)The AHA is a Rasch analysed measure of
bimanual hand performance [73]. The AHA is a
performance measure and examines the
effectiveness with which a child with a unilateral
impairment spontaneously or typically uses their
impaired hand in bimanual activities [73]. The
test yields a range of scores between 22 and 88
which are subsequently scaled by transforming
the total raw score to a percentage and range
from 25 to 100. Conversion of these ordinal
scores into logits (log odds probability units) which
are equal interval measures is possible through
Rasch analysis. Inter-rater and intra rater reliability
is high for summed scores (ICC 0.98 and ICC 0.99
respectively). There are three versions of the AHA;
small kids, school kids and an adolescent version.
Test-retest reliability is high for small kids and
school kids (ICC 0.99 and 0.98 respectively.) The
AHA has demonstrated it is responsive to change
in many clinical studies [16,22,24,74,75]. Reliability
studies yielded a smallest detectable difference
(SDD) of 3.89 raw scores for the small kids and
3.65 raw scores for the school kids version [76].
For this study, the AHA will be scored by two
certified raters whom will be masked to group
allocation and order of assessment. Scores will be
transformed into logits for ease of interpretation.b) Unimanual capacity
i. The Melbourne assessment of Unilateral Upper
Limb function (MUUL)
The MUUL measures both upper limb
impairment and quality of upper limb function
[77]. It is designed for children aged 5–15 years
with CP, and consists of sixteen criterion-
referenced items measuring aspects of reach,
grasp, release and manipulation. A set of scoring
criteria for each item examines the quality of
range of motion, accuracy, fluency and dexterity.
The maximum possible raw score is 122, and raw
scores are computed into percentage scores.
Inter-rater and intra-rater reliability for the
MUUL is very high for total test scores (ICC 0.95
and 0.97 respectively) and moderate to high for
individual items (ICC 0.69 – 0.91). Test-retest
reliability is high for total test scores and
moderate to high for items [28]. The MUUL has
good internal consistency (Cronbach’s alpha
α=0.96) [28]. Construct and content validity for
the MUUL was established during test
development [77]. Previous results of a reliability
study found a change of 12% for intra-rater
reliability and 14% for inter-rater reliability wasrequired to suggest a clinically significant effect
[77]. More recent studies investigating reliability
suggested the smallest detectible difference
ranged from 7.4% [78] to 8.7% [79]. The MUUL
has recently undergone Rasch analysis and
unidimensionality of the scale was not confirmed
[80]. Four distinct subscales were identified
however, with only preliminarily evidence; it
remains unclear whether any of the subscales will
be better able to detect change following UL
intervention [80]. Establishment of intra-rater
reliability for the COMBiT study will be
conducted to determine the SDD and define
children who achieve a significant clinical
response. The MUUL will be videotaped in
accordance with the manual guidelines and will
be later scored by an experienced occupational
therapist masked to group allocation and order of
assessment.Secondary outcomes
Unimanual capacity
i. Jebsen Taylor Test of Hand Function (JTTHF)
The JTTHF measures unilateral speed and dexterity
on timed tasks [81]. The test measures speed and
accuracy of performance on various complexities of
grasp and release. The original test was designed and
validated in adults and typically developing children
and has been modified to exclude the writing task
and reduced the maximum allowable time of each of
the remaining six tasks to two minutes when utilised
in children with congenital hemiplegia [25,75,82,83].
The JTTHF has been shown to be responsive to
change due to an intervention [74]. There are
concerns regarding the stability of test-retest
performance in the unimpaired limb [74,75,82,83].
The test retest reliability and concurrent validity of
the JTTHF with the Box and Blocks Test in children
with congenital hemiplegia will be determined as
part of the COMBiT study.
ii. Box and Blocks Test (BBT)
The BBT is a measure of gross manual dexterity
[84]. It was initially developed specifically for use in
adults with cerebral palsy the test comprises of a
wooden box (53.7 cm × 25.4 cm) which is divided
by a 15.2 cm high partition to form two equal
compartments. 150 coloured wooden blocks all
2.5 cm in size are placed in one compartment. The
participant is required to transfer as many blacks
from one compartment to the other in 60 seconds.
The score is the number of wooden blocks
transferred in one minute [84,85]. Concurrent
validity of the BBT is supported by a good
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Manipulation Test (r=0.91) and the General
Aptitude Test Battery, Part 10 (r=.86). Inter rater
reliability of the BBT was r = 1.00 and r = 0.999 for
the right and left hands respectively. The reported
test-retest reliability of the BBT (at six months) is
ρ = 0.976 and 0.937 for right and left hands
respectively [84]. Norms for 6–19 year olds are
available [84].Bimanual performance
(i) Children’s Hand-Use Experience Questionnaire
(CHEQ)
The CHEQ is a Rasch analysed questionnaire for
children and youth (6 to 18 years) that examines
their experience of using their impaired hand during
bimanual activities [86]. Participants are required to
answer twenty nine questions related to bimanual
activities and identify their level of independence
and whether one or two hands are used to complete
the task. Three scales of perceived efficacy of grasp,
time taken to complete the activity and degree of
feeling of being bothered doing the activity are also
rated for each of the bimanual activities. Summary
scores for the questions can be generated, but for
participants in a research trial, raw data will be
transformed into logit scores by the test developers
[86]. The CHEQ has not yet been used in clinical
trials, and its sensitivity to change will be examined
as part of the COMBiT study.Participation outcomes
(i) Assessment of Life Habits (LIFE-H for children
version 1.0)
The LIFE-H® [87] is designed for children aged 5 to
13 years and measures life habits in home, school
and neighbourhood environments [87]. It is a
questionnaire completed by the parent/caregiver
about the child. The long form consists of 197 items
divided into 12 categories and includes regular
activities (eating meals, communication, and
mobility) and social roles. A weighted score ranging
from 0 to 10 is generated for each category and
overall total. Construct validity was established
during test development [87] and criterion validity
with strong correlations between the LIFE-H and
PEDI and Functional Independence Measure for
Children (WeeFIM) are reported [88]. Adequate to
excellent internal consistency (Cronbach’s α = 0.73 –
0.90 for categories, 0.97 for daily activities and 0.90
for social roles), intra-rater (ICC = 0.83 – 0.95 for
daily activities), inter-rater (ICC = 0.8 – 0.91 fordaily activities and 0.63 – 0.9 for social roles) and
test-retest reliability (ICC = 0.73 for total score)
have been established [89]. Four categories,
reflecting the particular areas of difficulty in hand
use and independence in daily life typically
experienced by children with hemiplegia, will be
evaluated in this study including nutrition
(eg. mealtime activities), personal care (eg. dressing),
education and recreation.Quality of life outcomes
(i) The Cerebral Palsy Quality of Life questionnaire for
children (CPQOL-child)
The CPQOL will be used to investigate quality of life
from the perspectives of parents (CPQOL Primary
Caregiver Questionnaire) and from the children
themselves (children and youth of nine years or
older- the CPQOL Child Report Questionnaire) [90].
The CPQOL-Child is a condition specific measure
across seven broad domains of quality of life: social
wellbeing and acceptance, functioning, participation
and physical health, emotional wellbeing, access to
services, pain and impact of disability and family
health. Psychometric properties of the CPQOL are
excellent with Cronbach’s α ranges from 0.74-0.92
(parent proxy report) and 0.80-0.90 (child self
report) [91]. Adequate test re-test reliability (ICC =
0.76-0.89) is reported with moderate correlations
with the CHQ, KIDSCREEN, and GMFCS. The
CPQOL-teen version for youth 14–18 years has
adequate correlations with a generic QOL
instrument for both parent report (r = 0.40-0.46)
and teen self report (r = 0.58-0.68) [92,93].Individualised occupational performance goals
(i) Canadian Occupational Performance Measure
(COPM):
The COPM is a standardised individualised, client
centred measure that evaluates client’s self-
perception of occupational performance over time
[94]. Participants identify areas of difficulty in
everyday occupational performance across the
domains of self-care, leisure and productivity and
rate their performance and satisfaction for each
problem on a scale from one to 10 [94]. An average
score for performance and satisfaction is calculated.
There is good evidence of construct, content and
criterion validity [95-97]. The retest reliability of the
performance and satisfaction scores on the COPM is
high (ICC = 0.76-0.89) [98,99]. The COPM has
demonstrated responsiveness to change in paediatric
clinical trials [100,101] with a 2 point change on
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significant [94]. In the present study, the COPM will
form the basis of goal setting for therapy. The
COPM will be administered by one of the study
occupational therapists. Children aged 8 years and
older will be encouraged to identify three to five
goals and rate their perceived level of performance
and satisfaction on the 10-point scale in
collaboration with their primary caregivers. For
younger children or those with intellectual
impairment, parent/caregivers will complete the
COPM with input from their child.Environmental measures
(i) Study questionnaire
A study questionnaire has been developed to
capture demographic information that has been
shown in the literature to influence a child’s
outcomes. Information will be collected on child’s
age and gender, socio-economic status, family
structure and supports, family income and current
involvement in rehabilitation programs.(ii)The Parenting Scale
The Parenting Scale [102] is a 30-item questionnaire
measuring three dysfunctional parenting styles:
laxness (permissive, inconsistent discipline); over-
reactivity (harsh, emotional, authoritarian discipline
and irritability); and verbosity (lengthy verbal
responses) [103]. All 30 items are scored on a seven
point scale, with low scores indicating good
parenting practices and high scores indicating
dysfunctional parenting. The Parenting Scale will be
completed by the primary caregiver during baseline
assessments and an overall measure of laxness, over
reactivity and verbosity will be calculated. The total
scaled score (the sum of all items divided by 30) will
be used as the primary measure of parenting style in
analyses. The Parenting Scale has demonstrated
adequate internal consistency (α’s for subscales
ranging from 0.78 to 0.85), good test-retest reliability
(r = 0.84 for the total score), an ability to
discriminate parents of clinic versus non-clinic
children, and correlations with observed parenting
style and child behaviour [102-104].Motivation
(i) The Dimensions of Mastery Questionnaire (DMQ)
The DMQ provides a primary caregiver’s and child’s
self-perceptions of mastery motivation [105]. It
consists of 45 items across seven subscales and twoaspects of mastery motivation. Instrumental mastery
focuses on persistence with tasks and includes the
subscales of object-oriented persistence, gross motor
persistence, social persistence with adults and social
persistence with peers. Expressive mastery comprises
subscales of negative reactions to failure and mastery
pleasure. The final subscale, competence, is
considered a separate construct which measures the
child’s ability to master tasks relative to peers [105].
The DMQ takes approximately 15 minutes to
complete and will be administered with both
children and their primary caregivers according to
standard administration procedures. This involves
rating each of the 45 items on a five point scale
ranging from 1=not at all typical to 5=very typical.
Three is considered to be average for a typically
developing child of the same age. Higher scores are
considered to represent higher levels of motivation
[105]. To assist with understanding in the younger
age group (5 to 7 years) children may be prompted
with ‘smiley faces’ representative of the scores 1=not
at all typical through to 5=very typical. Seven
individual subscale scores are calculated by
summation of items in the subscale and dividing by
the number of items to obtain an average score
between 1 and 5. A total persistence score between
1 and 5 can be calculated from the average of the
four instrumental subscales. A total mastery
motivation score between 1 and 5 can also be
calculated based on the average of the four
instrumental subscales and the mastery pleasure
subscale. The DMQ total motivation score (average
of the four instrumental subscales and mastery
pleasure) will be used as the primary measure of
motivation as the DMQ total motivation score is
representative of the child’s overall motivational
predisposition including both instrumental and
expressive mastery motivation. Individual DMQ
subscale scores will be examined in secondary
analyses. Test construction and clinical utility of the
DMQ is satisfactory. The DMQ has high item
internal consistency with Cronbach’s α‘s greater than
0.74 [105]. Test retest reliability for parents of
preschool aged children is reported as high with
ICC’s between 0.74 and 0.82 on instrumental
subscales. Total score ICC’s are 0.76 with a standard
error of measurement (SEM) of 7.31 [106].
Construct validity is strong with clear factorial
evidence for scales on principal component analysis
[106]. The psychometric properties and clinical
utility of this measure have recently been evaluated
as part of a systematic review of measures of
motivation in school aged children with a physical
disability or motor delay [107]. The test retest
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aged children will be investigated as part of this
study.
(ii)The Pediatric Volitional Questionnaire (PVQ)
The PVQ is an observational assessment whereby
the child’s volition is scored according to motivation
and mastery behaviours observed during different
activities [108]. This requires therapy sessions to be
videotaped so that the child’s motivation and
mastery behaviours when faced with therapy tasks of
varying challenge can be observed. The PVQ has a
four point scoring system where 1=passive through
to 4=spontaneous. A mean level of volition ranging
between 1 and 4 is calculated by summing all scores
and dividing by the number of items (i.e. 14). The
methodological quality of psychometric studies for
the PVQ is poor based on very small samples sizes.
Within these studies, the PVQ demonstrated
adequate evidence for construct and criterion
validity with Rasch analysis identifying good item
spread (−0.96 to 1.34 logits) and no misfitting items
[109]. Mean difficulty of items (0.00±0.66) and mean
ability of participants (0.68±0.99) was well spread
[109]. Reliability of the PVQ was weak with evidence
of poor inter rater reliability (rater separation 4.11)
[109]. For this project, the PVQ will be rated by the
same rater. The psychometric properties and clinical
utility of the PVQ measure will be evaluated as part
of this study.
Therapist observations and evaluation
Therapist observations and evaluation of the child’s en-
gagement, participation, persistence, task direction and
task pleasure will occur during therapy sessions. This re-
quires therapists to complete two Likert scales on task
persistence and affect at the end of each therapy session.
To assist in completing these scales the therapist will ob-
serve the following behaviours during sessions:
a. Persistence with a challenging problem, skill or task.
Observation of the amount of task directed – is
important in evaluating persistence. Greater
persistence indicates greater mastery behaviour –
which includes trying successfully or unsuccessfully to
solve the problem or master the task motivation [110].
b. Embracing rather than avoiding challenge. Choosing
challenging tasks in preference to easy ones indicates
greater mastery motivation [110].
c. Displays of positive affect (smiling, pleasure, pride)
associated with persistence. Positive displays of
mastery (task) pleasure indicate higher levels of
motivation [110].
d. Prematurely requesting help and avoiding challenges
which indicate lower mastery motivation [110]e. Any negative reactions and emotional responses to
failure.
At the end of every therapy session therapists will evalu-
ate the most common or predominant motivational be-
haviour observed. This will be measured on two scales:
i. The Task Directed and Persistence Scale: determines
on a scale of 1 to 9 how task directed, persistent,
goal focused and motivated a child was during the
therapy sessions
ii. The Child’s Affect Scale: determines on a scale of 1
to 9 the level of positive affect demonstrated by a
child during therapy sessions.
Post intervention interviews
The above measures will be supplemented with individ-
ual semi structured interviews post training to identify
experiences of children participating in COMBiT, to gain
insights into their experience of the day camp. Video
footage of training sessions will be presented to facilitate
interviews and discussions with children and their pri-
mary caregivers. Interviews will be videorecorded and
transcribed verbatim.
Blinding
Functional MRI data will be qualitatively analysed by
neurologists masked to group allocation. Paediatric neu-
rologists with fMRI training will independently rate
scan quality (0–5), region of activation, change over
time and patterns of reorganisation. Data for AHA and
MUUL will be rated from videos masked to order and
group allocation.
Adverse events
Any minor and major events associated with intramus-
cular BoNT-A injections prior to the training study or
due to either training model will be screened at 2 weeks
by open-ended questions. If temporary weakness occurs
following intramuscular BoNT-A injections, this can be
addressed during the training programs. Any adverse
events or unintended effects detected will be reviewed
by a Rehabilitation Physician.
Statistical analyses
Analysis will follow standard principles for RCTs, using
two-group comparisons on all participants on an intention-
to-treat basis. Primary analyses will include all evaluable
data. Sensitivity analyses will use imputation techniques to
account for potential bias as a consequence of non-
ignorable missing data during follow-up. The primary com-
parison H1 at 6 months will be based on the AHA and
MUUL scores and will be between treatment groups using
generalized linear models, with terms included to account
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as baseline unimanual capacity. Secondary analyses will use
similar methods to compare the outcomes between groups
for participation (domains of LIFE-H) and QOL (domains
of CP-QOL). Where continuous data exhibit skewness not
overcome by transformation, non-parametric methods
(e.g. Mann–Whitney U Test) will be used for simple
comparisons.
For H2: The magnitude of central neurovascular
changes between groups will be determined using quan-
titative analysis of fMRI statistical parametric maps will
be performed using iBrain™: regions of interest will be
delineated for each individual (primary motor cortex
PM1, supplementary motor area (SMA), and ipsilateral
motor cortex (PM1ipsi) and active voxels in those re-
gions will be counted. These data will be compared for
each region over time using generalised estimating
equations approach. In subjects where mirror move-
ments did not occur, lateralisation between ipsilateral
and contralateral PM1 will be assessed using an object-
ive approachCIC#188 to determine the incidence and
magnitude of brain reorganisation. Statistical signifi-
cance will be at p<0.05.Discussion
This paper presents the background and design for a
matched pairs randomized trial comparing an intensive
block of combined mCIMT and BIM training (COMBIT)
to a distributed standard care model of upper limb re-
habilitation for children with congenital hemiplegia. To
our knowledge this is the first study to directly compare
the density of upper limb training, a block of intense
COMBiT compared to an equal dose of a distributed
model of individualised training. Furthermore, we will
be evaluating the outcomes of the intervention program
across all domains of the ICF using valid and reliable
measurement tools.Additional file
Additional file 1: Table S1. COMBIT weekly program example.Abbreviations
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